ReviewCardiovascular intervention and therapeutics2021
Drug-eluting stent thrombosis: current and future perspectives.
Review in Cardiovascular intervention and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Drug-Coated Balloons Versus Other Percutaneous Coronary Intervention Strategies in De Novo Coronary Artery Disease: A Systematic Review, Meta-Analysis With Trial Sequential Analysis.Cardiovascular therapeutics · 2026Pooled it
- Systematic Review on Role of Drug Eluting Stent (DES) Versus Drug-Coated Balloon (DCB) in Small Vessel Coronary Artery Disease.Current cardiology reports · 2024Pooled it
- Drug-coated balloons versus drug-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention: an updated meta-analysis with trial sequential analysis.BMC cardiovascular disorders · 2023Pooled it
- Drug-Coated Balloon vs. Stent forFrontiers in cardiovascular medicine · 2021Pooled it
- Thrombocytopenia as a Bleeding Risk Factor in Atrial Fibrillation and Coronary Artery Disease: Insights From the AFIRE Study.Journal of the American Heart Association · 2023Trial
- Cardiovascular stent technologies for coronary and valvular heart disease: the potential of 3D printing for stent fabrication.Nature reviews. Cardiology · 2026Review
- A Comprehensive Numerical Simulation on the Safety and Efficacy of Circular-Versus Trapezoidal-Shaped Intravascular Drug-Eluting Stents.International journal for numerical methods in biomedical engineering · 2026Article
- Adjunctive therapeutic strategy for in-stent thrombosis:RSC advances · 2026Article
- Risk factor analysis and machine learning-based prediction model for type 4b acute myocardial infarction induced by very late stent thrombosis.BMC cardiovascular disorders · 2026Article
- Five-year mean follow-up of NeoHexa sirolimus eluting coronary stent: A retrospective evaluation of long-term safety and efficacy.World journal of cardiology · 2026Article
- Comparison of different interventional treatment strategies for patients with type 4b acute myocardial infarction caused by very late stent thrombosis.Scientific reports · 2025Article
- Transient receptor potential canonical 3/5 attenuate endothelial damage-induced neointima formation without affecting endothelial cell proliferation.European journal of histochemistry : EJH · 2025Article
- 3D printing of stents via two-photon polymerization.Scientific reports · 2025Article
- Drug Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons.Pharmaceutics · 2025Article
- Stent thrombosis: a contemporary guide to definitions, risk factors, and management.Frontiers in cardiovascular medicine · 2025Review
- Platelets, Biomarkers of Coagulation and Fibrinolysis, and Early Coronary Stent Thrombosis.Journal of clinical medicine · 2024Article
- Off-pump coronary artery bypass grafting versus percutaneous coronary intervention with second-generation drug-eluting stents for coronary artery revascularization.The Journal of international medical research · 2024Article
- Identification of endothelial protein C receptor as a novel druggable agonistic target for reendothelialization promotion and thrombosis prevention of eluting stent.Bioactive materials · 2024Article
- Coronary artery bypass graftingJournal of thoracic disease · 2024Article
- FeMaterials today. Bio · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 40 years, the safety and efficacy of percutaneous coronary intervention has dramatically improved by overcoming several challenges. The introduction of drug-eluting stent (DES) in particular was a major breakthrough in interventional cardiology. Compared to bare-metal stents, first-generation DES (G1-DES) has dramatically reduced the rates of in-stent restenosis and subsequent target lesion revascularization. However, major safety concerns surrounding stent thrombosis (ST) emerged with G1-DES in clinical practice as a result of the high incidences of death, myocardial infarction, and repeat revascularization associated with ST. To overcome these limitations, second-generation DES (G2-DES) has been developed with an improved stent platform with thinner strut and biocompatible durable or biodegradable polymers. Indeed, G2-DES, when compared with G1-DES, has improved clinical outcomes by reducing the risk of late thrombotic events while maintaining anti-restenotic efficacy, whereas ST still occurs, even with the use of G2-DES. This review gives an overview of pathophysiology, risk factors, and outcomes of ST after DES implantation. Additionally, we discuss the management and prevention of ST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.